Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 5/20 | 0.43 |
| ▸ | PAK4 | O96013 | 3/20 | 0.43 |
| ▸ | IGF1R | P08069 | 9/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.36 |
| ▸ | PAK3 | O75914 | 2/20 | 0.36 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15059707 | 0.88 | IGF1R (0.38) | MKNK1MKNK2ROCK2ROCK1PAK1 | |
| SCHEMBL15208674 | 0.85 | ROCK2 (0.41) | MKNK1MKNK2ROCK2ROCK1PAK1 | |
| SCHEMBL15059155 | 0.84 | MKNK1 (0.53) | MKNK1MKNK2ROCK2ROCK1PAK1 | |
| SCHEMBL15208256 | 0.84 | ROCK2 (0.40) | MKNK1MKNK2ROCK2ROCK1PAK1 | |
| SCHEMBL15059363 | 0.84 | MKNK1 (0.41) | MKNK1MKNK2ROCK2ROCK1PAK1 | |
| SCHEMBL15208562 | 0.83 | CCNT1 (0.41) | MKNK1MKNK2ROCK2ROCK1PAK1 | |
| SCHEMBL14722792 | 0.82 | ROCK2 (0.40) | MKNK1MKNK2ROCK2ROCK1PAK1 | |
| SCHEMBL15058643 | 0.81 | PAK1 (0.47) | MKNK1MKNK2ROCK2ROCK1PAK1 | |
| SCHEMBL15059672 | 0.81 | PAK1 (0.61) | MKNK1MKNK2ROCK2ROCK1PAK1 | |
| SCHEMBL15059562 | 0.79 | ROCK2 (0.41) | MKNK1MKNK2ROCK2ROCK1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794605-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | claimed |
| US-8815877-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | claimed |
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-07-11 | — | — | US | claimed |
| WO-2013092940-A1 | 2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178486-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, PAK3 | MKNK1 193/4885MKNK2 207/4885ROCK2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.